IL-2: a review of current knowledge

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Expanding T-cells for cancer therapy has been limited.
• Recombinant interleukin-2 (r-IL-2) enables T-cell and LAK cell expansion.
• Tumor-infiltrating lymphocytes are known to be cytolytically active.

Purpose of the Study:

• To confirm the feasibility of expanding T-cells and LAK cells for clinical trials.
• To demonstrate the anti-tumor activity of expanded T-cells and LAK cells.
• To explore laboratory-based technology for advanced cancer treatment.

Main Methods:

• Expansion of T-cells and LAK cells using r-IL-2.
• Confirmation of anti-tumor activity in murine models.
• Utilizing IL-2 stimulation and ongoing antigen stimulation from tumor cells.
• Defining factors that support T-cell growth and activation.
• Employing tumor cell cultures and purified antigen for repeated antigen stimulation.

Main Results:

• Feasibility of T-cell and LAK cell expansion confirmed.
• Demonstrated anti-tumor effects in murine models and patients with various cancers, including melanoma and renal cancer.
• Selective killing of tumor cells achieved through IL-2 and antigen stimulation.
• Preliminary results indicate a significant change in cancer treatment technology.

Conclusions:

• Adoptive cellular biotherapy using expanded and activated T-cells is a viable method for treating advanced cancer.
• Laboratory-based technology, including tumor-derived activated cell (TDAC) stimulation, expansion, and therapy, offers a broad attack on cancer.
• Close collaboration between laboratory scientists and clinicians is crucial for translating these technologies to patient care.